MDT vs PHG: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of September 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MDT and PHG share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MDT and PHG exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans four main areas: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform), and Diabetes (insulin pumps and continuous glucose monitoring). The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics.

Full MDT guide

Koninklijke Philips N.V. (Royal Philips) is a Netherlands-based health-technology company that generated roughly EUR 17.8 billion (about $19 billion) in 2025 sales across three segments: Diagnosis and Treatment (imaging systems, image-guided therapy, ultrasound), Connected Care (patient monitoring, hospital informatics, and its Respironics sleep and respiratory business), and Personal Health (electric shavers, toothbrushes, and mother-and-child care). US investors most commonly access it through the PHG American Depositary Receipt on the NYSE, which represents ordinary shares that also trade in Amsterdam; the ADR structure means currency moves between the euro and the dollar affect the quoted price and the dividend.

Full PHG guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.
• PHG drivers: Margin recovery and cost discipline; Order intake and installed-base momentum.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. For PHG, china remains a drag, hurt by industry-wide anti-corruption measures, subdued demand, and share losses in imaging, and a single soft quarter there has moved the stock sharply in the past.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MDT if you believe its drivers more; PHG if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MDT and PHG guides.

MDT. Medtronic trades at a moderate valuation relative to faster-growing medtech peers, reflecting its scale, diversification, and reliable dividend but also a track record of slower organic growth. The multiple has expanded when new product cycles reaccelerated growth and compressed during periods of execution stumbles. The yield gives it a defensive, income-oriented profile within healthcare.

PHG. Philips trades at a trailing P/E in the low-20s that compresses to the mid-teens on a forward basis, reflecting expectations that margin recovery lifts earnings. The stock carried a market cap around $27 billion in mid-2026 on roughly $19 billion of sales, a price-to-sales near 1.3x. Figures are approximate, reported in euros, and converted to dollars at prevailing rates for the ADR.

Headline figures (approximate, early 2026): MDT shows revenue (ttm) ~$33 billion, operating margin ~20% (non-GAAP higher; GAAP affected by amortization), net income (ttm) ~$4.5 billion, eps (ttm) ~$3.50 GAAP; non-GAAP higher; PHG shows revenue (2025) ~EUR 17.8B (~$19B), net income (2025) ~EUR 897M, adjusted ebita margin (2025) ~12.3%, market cap ~$27B.

MDT and PHG are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MDT and PHG exposure against your real portfolio. It is not an investment adviser.